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A) The blood-brain barrier (BBB) is created by tight junction (TJ) formation at the level of the cerebral capillary endothelial cells. It is by far the largest surface area for blood -CNS exchange, and it covers between 12 and 18 m 2 in an average human adult [36] . and pathologically [4] .
The blood-brain barrier in brief
A close inductive association of several cell types, especially the end feet of astrocytic glial cells, maintain the differentiation of the endothelium into a barrier layer [4, 49] .
The supporting roles in barrier induction, maintenance and function are performed by pericytes, microglia and neural terminals, which are also closely associated with the endothelium [4, 37] . The hyperaemia of brain is accomplished by a group of cells, closely related to each other, called the neurovascular unit (NVU). The NVU is composed of neurons, astrocytes, endothelial cells of the BBB, myocytes, pericytes and extracellular matrix components [32] .
The role of TJs (zonulae occludentes) is a significant reduction of the permeation of ions and polar solutes, primary to maintain the ionic homeostasis in the brain. This permeation is carried through paracellular diffusional pathways between the endothelial cells from the blood plasma to the brain extracellular fluid [7, 49] .
TJs consist of a complex of proteins spreading across the intercellular cleft, such as occludin and claudins, and junctional adhesion molecules (JAM) [48, 49] . Cytoplasmic scaffolding and regulatory proteins ZO-1, ZO-2, ZO-3 link the junctional molecules occludin and claudins to intracellular actin and the cytoskeleton via cingulin [31, 48, 49] .As A b b o t t and colleagues [3] reviewed, the disappearance of either claudin-3 or claudin-5 from the tight junctional complexes might result in a compromised BBB.
Adherent junctions (AJs) and TJs are part of the junctional complexes between endothelial cells. In AJs, cadherin proteins spread across the intercellular cleft and are linked into the cell cytoplasm by alpha, beta and gamma scaffolding proteins. The AJs give structural support to the tissue by holding the cells together, and are essential for formation of TJs. The disruption of AJs gradually leads to the disruption of the barrier [48] .
Permeability of the BBB
As S a u n d e r s et al. [44] reviewed, several studies observed that parenteral injections of trypan blue and other acidic dyesin animal models stained almost all tissues except the brain. These experiments were followed by subsequent studies,which were using embryos or the newborn of various species. Most of them gave the same result as in adults, whereas most of the brain was not stained aside from the circumventricular organs, which led to the con- [45] . The BBB keeps optimal ionic composition for synaptic signalling function by a combination of specific ion channels and transporters, and thus provides a stable environment for the function of neurons [4, 10] . Since the central and peripheral nervous system both use many of the same neurotransmitters, separating the neurotransmitter pools controls "cross-talk" interference between the two signalling networks [1] . As a typical example serves gluta-mate, a neuroexcitatory amino acid which blood plasma levels significantly fluctuate after the ingestion of food [4, 10] . Similar to neurotransmitter levels, the protein content in the cerebrospinal fluid (CSF) is much lower than that of the plasma, with a different protein composition. Plasma proteins such as albumin, plasminogen or prothrombin are damaging to neural tissue, which in the final analysis can lead to apoptosis [23, 35] . If the BBB is damaged, these large serum proteins are able to leak into the brain and can cause serious pathological consequences.
The BBB also contributes to the brain homeostasis by protecting the CNS from various neurotoxic substances circulating in the blood, such as endogenous metabolites, xenobiotics or exogenous substances otherwise acquired from the environment. The level of neurogenesis is relatively low compared to the continuous steady rate of neuronal cell death throughout life, therefore any acceleration in the natural rate of cell death resulting from an increased access of neurotoxins into the brain would become prematurely impairing [27] .
The neural tissue requires a low passive permeability of the BBB to many essential water-soluble nutrients and metabolites, while lipid soluble substances are able to cross the barrier passively by diffusion. Therefore, to ensure an adequate supply of water soluble substances, specific transport systems are expressed in the BBB [4, 49] . In addition to the unidirectional and bidirectional transport of small molecules, some substances are able to enter the brain tissue from the blood by other ways, e. g. facilitated diffusion
(glucose via GLUT-1) or a receptor-mediated endocytosis (transferrin or insulin) [25] .
Changes in BBB permeability
The BBB as a dynamic system, is capable of responding to local changes and requirements. Its regulation serves for the adjustment of nutrient supply, protection from circulating agents, or modification to ease local repairs [4] .
A number of mechanisms and cell types are able to regulate the BBB in both physiological and pathological conditions.
For example, apical cell-cell junction interactions participate in the regulation of gene expression, cell proliferation, polarity and apoptosis using different types of proteins. The
TJs are one type of such cell-cell junctions and associate with several signalling complexes. Expression of TJ components allows cell differentiation by suppressing proliferation. These components affect several signalling and transcriptional pathways, and changes in the expression of TJ proteins are associated with several disease conditions. The aforesaid regulation includes changes in the function ofTJs [6] , and in the expression and activity of many transporters and enzymes [4, 17] . It appears that intracellular scaffold proteins ZO-1, ZO-2 and ZO-3 regulate the effectiveness of the TJs [48, 49] . Furthermore, many of the cell types associated with brain microvessels, such as astrocytes and microglia, release cytokines and vasoactive agents, which can modify the TJ assembly and barrier permeability [4, 41] .
Also, alterations in both intracellular and extracellular cal- [3] . The solute carriers may be unidirectional either into or out of the cell, bi-directional, they may involve an exchange of one substrate for another, or be driven by an ionic gradient. In the last case, the direction of transport is reversible depending upon the electrochemical gradient [3] .
A large spectrum of lipid-soluble molecules are able to passively diffuse through the BBB and enter the brain [28] .
There is a general interrelation between the rate at which a solute enters the CNS and its lipid solubility. It is usually The movement of the blood gases, oxygen and carbon dioxide, across the BBB is diffusive as well, and the dissolved gases move down their concentration gradients [3] .
Mononuclear cells appear to be able to penetrate directly through the cytoplasm of the endothelial cells by a process of diapedesis, which enables them to cross the BBB without disruption of TJs [19, 50] . During diapedesis, the fluid-filled channel through the cell is never created.
The leukocyte enters the endothelial cell with the luminal membrane closing over it before it creates an opening in the abluminal membrane [12, 50] . produce, have a faster organ clearance [30, 51] , penetrate the solid tumours more efficiently [53] , and are more suitable for structural analysis [29, 42] .
Nanobodies
In the early 1990s it was discovered that the antibody repertoire of camelids contains antibodies consisting of heavy chains only, which are referred to as heavy-chain antibodies (HCAbs) [24] . and CH3, while the CH1 domain known from conventional antibodies is missing [24] . With approximately 15 kDa
VHHs are the smallest naturally derived antigen-binding antibody fragments. Recombinantly produced VHH fragments are also called "nanobodies" [34] . The advantages of nanobodies include: small size (2.5 nm in diameter and about 4 nm height), recognition of unique epitopes, high affinity, high solubility, high stability, and high expression yields in heterologous expression systems [15, 22] .
As G h a s s a b e h et al. [22] reviewed, HCAbs have also been described in humans as a pathological disorder termed "heavy chain disease. " However, these human 
Transport of nanobodies across the BBB
The BBB is only permeable to lipophilic molecules of up to 400 Da in size [39] , therefore conventional antibodies are unable to spontaneously cross, given their average size is approximately 155 kDa [13] .The delivery of conventional antibodies to the brain is especially tiresome, due to Fc-receptor mediated efflux to the blood [16] , thus nanobodies lacking an Fc-part represent a promising alternative to brain targeting antibodies. Therapeutic application of nanobodies to CNS is difficult because the BBB restrain the delivery of intravenously injected nanobodies to the brain.
Various strategies have been developed and tested to overcome the BBB; for example, antibodies against receptors that undergo transcytosis across the BBB have been used as vectors to target drugs or therapeutic peptides into the brain [5] .
In a therapeutic experiment using the Hargreaves model of inflammatory pain (injection of inflammatory agents into the rat or mouse hind paw), F a r r i n g t o n et al. [20] tested the ability of FC5 nanobodies as a drug deliverer. It was shown that FC5 conjugated with opioid peptide Dal could be deployed as a drug delivery shuttle in vivo to induce a significant analgesic response in contrast to unconjugated Dal peptide. The FC5 is a nanobody, which selectively recognizes human cerebromicrovascular endothelial cells (HCEC) and transmigrates across them in vitro and across the BBB in vivo [33] . The same group later suggested that FC5 binds to a putative α (2,3)-sialoglycoprotein receptor ( Fig. 1A) and is transcytosed via clathrin vesicles [5] . The potential of the nanobody FC5 as a shuttlingnanobody can be used to transfer other therapeutics, e. g.
proteins or therapeutic nanobodies through the BBB [43] .
Receptor-mediated transcytosis for brain targeting was utilized also by W a n g et al. [47] . They showed that a fusioncomplex of a peptide derived from apolipoprotein E and a model therapeutic protein (α-L-iduronidase) could be transferred to the brain via binding to the LDL receptor expressed on cells of the BBB. Apolipoprotein E (ApoE) binds to alow density lipoprotein receptor-related protein 1 (LRP1) (Fig. 1B) inducing transcytosis, which can be used as a shuttle for therapeutic nanobodies in the future [43] .
Another research group studied the transferrin receptor and the insulin receptor ( Other studies reported that nanobodies with a high isoelectric point (pI)~9,5 [26, 33] spontaneously cross the BBB (Fig. 1D) . Such nanobodies easily gain access to the brain and even penetrate cells and bind to intracellular proteins. In a mouse study, L i et al. [26] used a recombinant nanobody E9 (pI = 9.4) directed against glial fibrillary acidic protein (GFAP), a specific marker of astrocytes. This nanobody crossed the BBB in vivo, diffused into the brain tissue, and was able to bind to intracellularly expressed GFAP in astrocytes. The FC5 nanobody described above has a basic pI 9.2 which might contribute to its transcytosis into the brain parenchyma [43] .
There are other possible routes of transport used in other therapeutics, which were not tested yet with nanobodies.
Ga i l l a r d et al. [21] have tested the use of CRM197, a nontoxic mutant of diphtheria toxin, as a targeting vector for drug delivery to the brain. CRM197 was tested for its brain delivery potential as it has been shown to endocytose after binding the membrane-bound precursor of heparin binding epidermal growth factor-like growth factor (HB-EGF), also known as the diphtheria toxin receptor. 
CONCLUSIONS

